搜索
 > 【SOST】重组蛋白信息

SOST信息

英文名称:Sclerostin
中文名称:硬化蛋白
靶点别称:SOST,Sclerostin
上市药物数量:1
临床药物数量:4
最高研发阶段:批准上市

SOST产品列表

SOST 分子别名

SOST,VBCH

SOST 分子背景

Sclerostin (SOST) is also known as Sclerosteosis, VBCH, is a secreted glycoprotein with a signal peptide for secretion and a C-terminal cysteine knot-like (CTCK) domain and belongs to the Cerberus/DAN family of bone morphogenetic protein (BMP) antagonists. Sclerostin is produced by the osteocyte and has anti-anabolic effects on bone formation. More recently Sclerostin has been identified as binding to LRP5/6 receptors and inhibiting the Wnt signalling pathway. Wnt pathway inhibition under these circumstances is antagonistic to bone formation (meaning Sclerostin antagonizes bone formation). It has been shown that SOST binds BMP-5, -6, and -7 with high affinity and BMP-2 and -4 with low affinity. Sclerostin production by osteocytes is inhibited by parathyroid hormone, mechanical loading and cytokines including oncostatin M, cardiotrophin-1 and leukemia inhibitory factor. Sclerostin production is increased by calcitonin. Thus, osteoblast activity is self regulated by a negative feedback system. Mutations of Sclerostin is associated with the syndrome Sclerosteosis, and reduced sclerostin expression results in a milder form of the disorder called van Buchem disease.

SOST 参考文献

SOST上市药物信息

英文名称 中文名称 研发代码 研发阶段 公司 最早商品名 最早批准国家 最早适应症 最早批准公司 最早批准日期 适应症 临床试验
Romosozumab AMG-785; CDP-7851,AMG785,CDP7851 批准上市 安进, 优时比, 安斯泰来 Romosozumab 日本 骨质疏松症 安斯泰来,安进,优时比 2019-01-08 00:00:00.0 骨质疏松症 详情

SOST临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
AMG-167 AMG-167 临床一期 安进 骨质疏松症 详情
Setrusumab BPS-804; MOR-05813 临床二期 MorphoSys, 诺华, Mereo BioPharma 成骨不全症 详情
Blosozumab LY-2541546,LY2541546 临床二期 礼来 骨质疏松症 详情
SHR-1222 SHR-1222 临床一期 江苏恒瑞, 上海恒瑞, 苏州盛迪亚 骨质疏松症 详情

消息提示

请输入您的联系方式,再点击提交!

确定